Emmanuella Amara Ofoka

Research Assistant Western Kentucky University Department of Biology

Bowling Green Kentucky, USA

[emmanuella.ofoka735@topper.wku.edu](mailto:emmanuella.ofoka735@topper.wku.edu), [emmanuellaamara@gmail.com](mailto:emmanuellaamara@gmail.com)

**Case Studies of Novel Diagnostics in Clinical Practice**

**Abstract**

The advent of novel diagnostics has revolutionized clinical practice by enhancing the speed, accuracy, and personalization of disease detection and management. This paper explores the transformative potential of advanced diagnostic tools such as liquid biopsies and point-of-care testing (POCT) providing some of the case studies associated with it. Liquid biopsy, exemplified through a case of bronchopulmonary adenocarcinoma, demonstrates the utility of non-invasive genetic mutation analysis in enabling targeted therapy and dynamic treatment monitoring. Similarly, POCT’s application in infectious disease management highlights its efficacy in providing rapid results, improving accessibility in resource-limited settings, and facilitating timely medical interventions. Despite these advancements, challenges such as high implementation costs, training requirements, and regulatory hurdles persist. The discussion emphasizes the need for collaborative efforts among stakeholders to address these issues and leverage innovations like artificial intelligence and bioinformatics for greater diagnostic precision. Ultimately, this paper discussed the role of novel diagnostics in reshaping healthcare delivery, improving patient outcomes, and paving the way for equitable, efficient, and personalized medicine.

**Keywords-** case study, novel diagnosis, point-of-care, liquid biopsy

**Introduction**

Novel diagnostics have emerged as a crucial aspect of clinical practice, aiming to enhance disease detection and treatment accuracy, efficiency, and speed (Alowais et al., 2023). These diagnostic tools are vital in improving patient outcomes across various medical fields by leveraging advanced technologies and innovative methodologies (Alowais et al., 2023). Molecular diagnostics have gained immense traction due to their ability to analyze genetic and molecular markers associated with diseases (Bajwa et al., 2021). These techniques enable the identification of specific pathogens or genetic mutations, leading to more accurate diagnoses. For instance, next-generation sequencing (NGS) allows for the identification of a broad range of genetic conditions and cancers, significantly improving diagnostic success rates in rare genetic diseases and complex tumors (Awad et al., 2021). The advent of accessible technologies has enabled the application of molecular diagnostics at the point of care, thereby expediting the diagnostic process. Technological advancements have transformed how diagnostics are conducted (Maleki Varnosfaderani & Forouzanfar, 2024). Tools such as portable diagnostic devices, like the GeneXpert Omni system, provide fast results for various conditions, including tuberculosis and HIV, within hours (Nayak et al., 2016). These devices have made it feasible to conduct tests in smaller clinics and even in remote areas, increasing accessibility to critical diagnostic services (Nayak et al., 2016). Furthermore, technologies such as microfluidics and smartphone dongles have facilitated rapid testing with high sensitivity and specificity, allowing for effective field diagnostics (Wang et al., 2023).

Despite the advancements, the integration of novel diagnostics into clinical practice faces several challenges. Issues such as the need for regulatory approval, cost-effectiveness, and training for healthcare providers remain pertinent (Peeling et al., 2021). Moreover, ensuring the accuracy and reliability of new diagnostic tools is crucial. For example, while rapid tests for infectious diseases have led to quicker diagnoses, the potential for false negatives or positives must be managed (Peeling et al., 2021).

The future of diagnostics in clinical practice is promising, with ongoing research aimed at refining existing technologies and developing new methodologies (Peeling et al., 2021). Efforts are being made to enhance bioinformatics capabilities to interpret complex datasets generated by advanced diagnostic tools. This will allow for better integration of data around patient care, ultimately aimed at personalized medicine (Liu et al., 2023). Additionally, emerging technologies in AI are expected to contribute to improved efficiency and accuracy in diagnostic decision-making, opening new avenues for patient management (Gala et al., 2024). ​In this review, we discussed how novel diagnostics reshape clinical practice, provide timely disease detection methods, and state some case studies of novel diagnostics in clinical practice: the novel clinical challenges and the potential for significantly improved patient care through these innovations.

**Real-world applications of novel diagnostics in infectious disease management**

The real-world applications of novel diagnostics in infectious disease management have been seen as significant advancements in recent years (Peaper et al., 2022). These innovations have aimed to improve infectious disease detection, identification, and treatment (Liu et al., 2023). These tests can be used in various environments, including remote healthcare facilities, reducing the time taken to diagnose infectious diseases. For instance, systems like the GeneXpert assay have revolutionized Tuberlousis (TB) diagnostics by allowing rapid detection of TB as well as rifampicin resistance within just a few hours, significantly outpacing traditional culture methods that take weeks to yield results (Boehme et al., 2011). A lot of people have been diagnosed with streptococcal (GAS) pharyngitis, this has led to the development of rapid antigen detection tests (RADTs) Unfortunately, physical examination and clinical findings are inadequate to diagnose GAS pharyngitis. As its symptoms closely resemble those of other infectious causes of pharyngitis. The Infectious Diseases Society of America (IDSA) recommends examination of this infection with RADTs as it is very fast and accurate (Thompson & McMullen, 2020). However, integrating novel diagnoses in clinical practice is essential in impacting patient outcomes. Recent studies have shown that multiplex PCR can identify multiple pathogens simultaneously from clinical samples, such as respiratory secretions during outbreaks of viral infections (Syed et al., 2024). This also permits more effective surveillance programs, facilitating quick containment measures during outbreaks (*International Experts Explore Diagnostics for Infectious Diseases* 1970).

The rapid identification of pathogens allows for timely targeted treatment, crucial in scenarios where empirical treatment could lead to adverse outcomes, such as in sepsis where misdiagnosis can be life-threatening (Chen et al., 2019). With the aid of novel diagnostic health care professionals can initiate appropriate treatment plans without unnecessary delays that typically arise from laboratory testing (Caliendo et al., 2013). Thus, novel diagnostics have helped mitigate the effects of antimicrobial resistance by accurately identifying the causative agent of infections and their sensitivities to antimicrobial agents, thereby promoting better stewardship of existing antibiotics (Chen et al., 2019).

**Importance of incorporating novel diagnostics into clinical practice**

Incorporating novel diagnostics into clinical practice is crucial because it allows for earlier disease detection, more accurate diagnoses, personalized treatment plans, and improved patient outcomes. It can lead to more efficient healthcare delivery by enabling faster diagnosis and targeted therapies, ultimately minimizing unnecessary interventions, and improving overall patient care (Croft et al., 2015). For instance, advanced molecular diagnostics can identify pathogens or genetic mutations quickly and accurately, allowing healthcare providers to make informed decisions rapidly (Hunter, 2017). Timely diagnoses can significantly reduce delays in treatment and improve prognostic outcomes, particularly in acute conditions where every moment counts. Providing accurate results in a shorter time frame directly influences the effectiveness of clinical interventions (Zimmern, 2009).

However, misdiagnosis is a substantial concern in healthcare, often leading to inappropriate treatment and adverse patient outcomes (Neale et al., 2011). The incorporation of advanced diagnostics can significantly mitigate this issue by providing more sophisticated tools for assessment (Hunter, 2017). For example, molecular diagnostics can utilize biological markers specific to diseases, thus enhancing differentiation between similar conditions (Zimmern, 2009). The integration of novel diagnostics is paving the way for personalized medicine, where treatments are tailored to the individual characteristics of each patient, including genetic makeup (Neale et al., 2011). Employing techniques such as genomic sequencing, clinicians can identify specific variants in patients and customize therapeutic strategies accordingly. This personalization can result in more effective treatment plans, minimizing trial and error in medication selection and increasing the likelihood of favorable outcomes (Neale et al., 2011).

Although the initial investment in advanced diagnostic technologies can be high, they tend to save costs in the long run by reducing the need for unnecessary tests and treatments associated with misdiagnosis (Schiff, 2009). Effective diagnostics lead to targeted interventions, translating to better resource allocation and potentially lower overall healthcare costs when considering the long-term management of chronic conditions (Croft et al., 2015).

**Support for Evidence-Based Practice**

The development and implementation of new diagnostic tools provide robust data that support evidence-based medical practice (Hunter, 2017). Reliable and valid diagnostic information aids in refining clinical guidelines and practice standards (Solga et al., 2020). This continued evolution promotes ethical and effective patient care, ensuring that medical decisions are grounded in sound scientific evidence (Solga et al., 2020). The importance of incorporating novel diagnostics into clinical practice cannot be overstated. These tools enhance diagnostic accuracy, reduce the risk of misdiagnosis, enable personalized medicine, improve economic efficiency, and support evidence-based practice(Caliendo et al., 2013). The ongoing integration of advanced diagnostic methodologies is vital for the evolution of healthcare practices and the provision of high-quality patient care. We are going to be discussing novel diagnosis for cancer and Infectious diseases case studies in this chapter.

**Case Study Example of a Patient Diagnosed with cancer through Liquid biopsy Testing**

Liquid biopsy has become a pivotal method for the diagnosis and management of various cancers, as illustrated by several case studies that highlight its utility in clinical practice (Ulivi et al., 2021). The following examples further demonstrate the applications and benefits of liquid biopsy in patients diagnosed with cancer.

**Case Study Example of a Patient Diagnosed with Cancer Through Liquid Biopsy**

The case involves a 61-year-old female patient, a former smoker with no significant personal or family history of cancer, who presented with severe deterioration in her general health in May 2022. She exhibited symptoms including profound fatigue, anorexia, nausea, and abdominal pain associated with hepatomegaly (Thomas et al., 2022). Her clinical evaluation revealed multiple hepatic lesions and lymphadenopathies, ultimately leading to a diagnosis of bronchopulmonary adenocarcinoma. Upon confirming the presence of the epidermal growth factor receptor (EGFR) mutation through the liquid biopsy, oncologists decided to initiate treatment with osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), on June 28, 2022 (Thomas et al., 2022). This decision was pivotal, as timely access to this targeted therapy was deemed necessary due to the patient’s deteriorating condition. Within one week of starting osimertinib, the patient experienced pronounced clinical improvement, including a decrease in oxygen requirements and an overall better performance status. By the end of treatment with osimertinib, the patient exhibited substantial clinical benefits, showing a partial morphological response on imaging and normalization of various laboratory parameters. Following up circulating tumor DNA (ctDNA) analysis revealed a drastic reduction in the EGFR DEL19 mutation levels to 3,763 copies per mL of plasma after one week, indicating a favorable response to the therapy. After two months, the patient returned to a clinically asymptomatic state, demonstrating the effectiveness of integrating liquid biopsy into routine cancer management (Thomas et al., 2022).

This case studies underscore the potential of liquid biopsy as an invaluable tool in the diagnosis and management of cancer.​ Liquid biopsy improves treatment decisions and patient outcomes across various cancer types by enabling non-invasive sampling and identification of actionable genetic mutations. The versatility of this methodology not only aids in initial diagnosis but supports ongoing monitoring and personalized treatment strategies, showcasing its growing importance in oncology (Thomas et al., 2022).

**Diagnosis Infectious Disease Through Point-of-Care Testing**

Traditional laboratory testing for infectious diseases often involves lengthy procedures that can delay diagnosis and treatment. These methods typically rely on cultures, which can take several days to yield results, and require specialized equipment and trained personnel (Priyanka et al., 2016). Conventional tests for pathogen identification often necessitate a prolonged turnaround time of 2 to 6 days, which can lead to significant delays in the initiation of treatment for patients suffering from infections (Priyanka et al., 2016). This extended waiting period is particularly detrimental in acute cases where timely intervention is critical for effective disease management (Kabiraz et al., 2023). Furthermore, many traditional diagnostic assays demand sophisticated laboratory settings and specialized personnel. to conduct the tests (Kabiraz et al., 2023). This requirement renders them less accessible, particularly in remote or resource-limited areas, where rapid response capabilities are paramount (Priyanka et al., 2016). The financial burden associated with traditional testing procedures can also be prohibitive, ideally in low-resource settings, potentially compromising patient care due to the unavailability of timely diagnostic services (Priyanka et al., 2016).

In response to these significant challenges, point-of-care testing (POCT) has emerged as a pivotal advancement in the field of diagnostics (Lazcka et al., 2007). POCT has transformed the landscape of medical testing by allowing diagnostic tests to be performed at or near the site of patient care, facilitating immediate clinical decision-making. ​A critical advantage of POCT is its ability to deliver results within minutes to hours, thus drastically reducing the time between diagnosis and initiation of appropriate treatment (Lazcka et al., 2007).​ This rapid turnaround is especially beneficial in emergency settings, where every minute counts, enabling healthcare providers to make timely decisions based on the latest data available. Moreover, many POCT devices are designed for ease of use, requiring minimal training for healthcare providers, enhancing their applicability in emergency and rural settings. This aspect is essential in areas where healthcare resources may be scarce, ensuring that even personnel with limited training can accurately conduct tests and respond to urgent medical needs (Lazcka et al., 2007). While some POCT devices may come with higher upfront costs, they can ultimately reduce the overall cost of care by minimizing hospital stays and promoting faster treatment initiation. The emergence of POCT signifies a critical shift toward more efficient and accessible healthcare, particularly in scenarios marked by urgency and resource constraints (Lazcka et al., 2007).

**Case Study Example of a Patient Diagnosed with an Infectious Disease Through Point-of-Care Testing**

Case Study 1: Rapid Testing for Malaria in Rural Africa

In a rural health clinic in sub-Saharan Africa, have a lot of cases of pregnant women and children presented with fever and chills (Wambani & Okoth, 2022) they were diagnosed with rapid diagnostic tests (RDT). Traditional diagnostic methods for malaria, such as microscopy, often take several days to yield results (Aidoo & Incardona, 2021). Utilizing an RDT for malaria, healthcare workers could provide results within 15 minutes (Zhang et al., 2024). The RDT confirmed a positive malaria infection, which enabled immediate treatment with artemisinin-based combination therapy (ACT) (Zhang et al., 2024). Following treatment, the patient showed substantial improvement, highlighting how POCT for malaria can facilitate timely diagnosis and treatment, ultimately reducing morbidity and mortality related to the disease (WHO, *Rapid diagnostic tests for malaria* 2021).

**Case Study 2: Point-of-Care HIV Testing in a Community Health Center**

The implementation of rapid testing enhances the diagnosis of HIV, and this has helped to reduce transmission of this infection among the population (Arora et al., 2013). However, the test can be done in under 10 minutes confirming the HIV status of the patient. This rapid diagnosis allowed for immediate counseling and antiretroviral therapy (ART) initiation (Arora et al., 2013). Subsequent follow-up indicated increased retention in care compared to traditional testing methods, often leading to treatment initiation delays (Trevino & Weissfeld, 2007).

**Case Study 3: Diagnosing Syphilis in Antenatal Care**

In a study conducted in a South American country, a pregnant woman was screened for syphilis using a rapid point-of-care test during her first prenatal visit. The RDT returned a positive result, leading to immediate treatment with benzathine penicillin. This timely intervention helped prevent potential congenital syphilis (García et al., 2013). Additionally, the García et al., 2013 study highlighted the importance of integrating POCT into routine antenatal care, significantly increasing the detection rate of syphilis and ensuring better maternal and neonatal health outcomes (García et al., 2013). These case studies collectively illustrate the transformative impact of point-of-care testing in diagnosing infectious diseases.​ Delivering rapid results facilitates immediate treatment, enhances patient care, and plays a vital role in controlling outbreaks. As healthcare systems adopt POCT, the potential for better health outcomes, especially in resource-limited settings, becomes increasingly clear.

**Discussion**

The integration of novel diagnostics into clinical practice represents a significant leap forward in the early detection, accurate diagnosis, and effective management of diseases. As demonstrated in this chapter, the development and application of advanced diagnostic tools, such as liquid biopsies (Ulivi et al., 2021) and point-of-care testing (POCT), have had transformative impacts across diverse medical fields. These technologies bridge the gap between traditional diagnostic methods and the growing demand for precision medicine, offering advantages in speed, accessibility, and personalization (Peeling et al., 2021).Liquid biopsy, as showcased in the cancer case study, underscores the power of non-invasive techniques in identifying actionable genetic mutations, such as the EGFR mutation in bronchopulmonary adenocarcinoma. The rapid initiation of targeted therapy, as illustrated, can lead to remarkable clinical improvements and better prognostic outcomes. This case study highlights the role of novel diagnostics in not only diagnosing complex diseases but also in monitoring treatment responses effectively. By reducing the need for invasive procedures and enabling dynamic disease tracking, liquid biopsies provide a compelling argument for their integration into routine oncology practice (Trevino & Weissfeld, 2007).Similarly, the use of POCT in infectious disease management exemplifies the role of rapid diagnostics in improving healthcare delivery, particularly in resource-limited settings. Malaria and HIV case studies emphasize how timely diagnosis facilitated by RDTs can drastically reduce morbidity and mortality (Kabiraz et al., 2023). POCT’s ability to provide immediate results at or near the point of care enables healthcare professionals to make informed decisions swiftly, reducing delays that often accompany traditional laboratory methods. These advancements are particularly impactful in regions with limited access to centralized healthcare infrastructure, where they support timely interventions and enhance patient outcomes.Despite these successes, challenges remain, the high initial costs of implementing novel diagnostic technologies and the need for specialized training and regulatory approvals are significant barriers to widespread adoption. Ensuring accuracy and reliability while minimizing false positives or negatives is another critical aspect requiring attention (Peeling et al., 2021). Addressing these challenges will necessitate collaboration among stakeholders, including healthcare providers, policymakers, and technology developers, to create an ecosystem conducive to innovation and equitable access.Looking ahead, the continued evolution of diagnostics, particularly with advancements in artificial intelligence and bioinformatics, holds immense potential (Liu et al., 2023). These technologies promise to enhance data interpretation, facilitate personalized medicine, and streamline the integration of diagnostic tools into clinical workflows.

Reference

Aidoo, M., & Incardona, S. (2021). Ten Years of Universal Testing: How the Rapid Diagnostic Test Became a Game Changer for Malaria Case Management and Improved Disease Reporting. The American Journal of Tropical Medicine and Hygiene, 106(1), 29. <https://doi.org/10.4269/ajtmh.21-0643>

Alowais, S. A., Alghamdi, S. S., Alsuhebany, N., Alqahtani, T., Alshaya, A. I., Almohareb, S. N., Aldairem, A., Alrashed, M., Saleh, K. B., Badreldin, H. A., Al Yami, M. S., Harbi, S. A., & Albekairy, A. M. (2023). Revolutionizing healthcare: The role of artificial intelligence in clinical practice. BMC Medical Education, 23, 689. <https://doi.org/10.1186/s12909-023-04698-z>

Arora, D. R., Maheshwari, M., & Arora, B. (2013). Rapid Point-of-Care Testing for Detection of HIV and Clinical Monitoring. International Scholarly Research Notices, 2013(1), 287269. <https://doi.org/10.1155/2013/287269>

Awad, A., Trenfield, S. J., Pollard, T. D., Ong, J. J., Elbadawi, M., McCoubrey, L. E., Goyanes, A., Gaisford, S., & Basit, A. W. (2021). Connected healthcare: Improving patient care using digital health technologies. Advanced Drug Delivery Reviews, 178, 113958. <https://doi.org/10.1016/j.addr.2021.113958>

Bajwa, J., Munir, U., Nori, A., & Williams, B. (2021). Artificial intelligence in healthcare: Transforming the practice of medicine. Future Healthcare Journal, 8(2), e188. <https://doi.org/10.7861/fhj.2021-0095>

Boehme, C. C., Nicol, M. P., Nabeta, P., Michael, J. S., Gotuzzo, E., Tahirli, R., Gler, M. T.,Blakemore, R., Worodria, W., Gray, C., Huang, L., Caceres, T., Mehdiyev, R., Raymond, L., Whitelaw, A., Sagadevan, K., Alexander, H., Albert, H., Cobelens, F., … Perkins, M. D. (2011). Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. *The Lancet*, *377*(9776), 1495–1505. <https://doi.org/10.1016/S0140-6736(11)60438-8>

Caliendo, A. M., Gilbert, D. N., Ginocchio, C. C., Hanson, K. E., May, L., Quinn, T. C., Tenover, F. C., Alland, D., Blaschke, A. J., Bonomo, R. A., Carroll, K. C., Ferraro, M. J., Hirschhorn, L. R., Joseph, W. P., Karchmer, T., MacIntyre, A. T., Reller, L. B., & Jackson, A. F. (2013). Better Tests, Better Care: Improved Diagnostics for Infectious Diseases. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 57(Suppl 3), S139. <https://doi.org/10.1093/cid/cit578>

Chen, H., Liu, K., Li, Z., & Wang, P. (2019). Point of Care Testing for Infectious Diseases. Clinica Chimica Acta; International Journal of Clinical Chemistry, 493, 138. <https://doi.org/10.1016/j.cca.2019.03.008>

Croft, P., Altman, D. G., Deeks, J. J., Dunn, K. M., Hay, A. D., Hemingway, H., LeResche, L., Peat, G., Perel, P., Petersen, S. E., Riley, R. D., Roberts, I., Sharpe, M., Stevens, R. J., Van Der Windt, D. A., Von Korff, M., & Timmis, A. (2015a). The science of clinical practice: disease diagnosis or patient prognosis? Evidence about “what is likely to happen” should shape clinical practice. *BMC Medicine*, *13*(1), 20. <https://doi.org/10.1186/s12916-014-0265-4>

García, P. J., Cárcamo, C. P., Chiappe, M., Valderrama, M., Rosa, S. L., Holmes, K. K., W. Mabey, D. C., & Peeling, R. W. (2013). Rapid Syphilis Tests as Catalysts for Health Systems Strengthening: A Case Study from Peru. PLOS ONE, 8(6), e66905. <https://doi.org/10.1371/journal.pone.0066905>

Gala, D., Behl, H., Shah, M., & Makaryus, A. N. (2024). The Role of Artificial Intelligence in Improving Patient Outcomes and Future of Healthcare Delivery in Cardiology: A Narrative Review of the Literature. Healthcare, 12(4), 481. <https://doi.org/10.3390/healthcare12040481>

Hunter, P. (2017). Novel diagnostic technologies for clinical and frontline use: Advanced diagnostics based on molecular markers and analysis technologies has been improving diagnosis across a wide range of diseases. EMBO Reports, 18(6), 881. <https://doi.org/10.15252/embr.201744423>

International Experts Explore Diagnostics for Infectious Diseases (1970) Global Health Press. Available at:https://id-ea.org/international-experts-explore-diagnostics-for-infectious-diseases/#:~:text=New%20technologies (Accessed: 19 December 2024).

Kabiraz, M. P., Majumdar, P. R., Mahmud, M. C., Bhowmik, S., & Ali, A. (2023). Conventional and advanced detection techniques of foodborne pathogens: A comprehensive review. Heliyon, 9(4), e15482. <https://doi.org/10.1016/j.heliyon.2023.e15482>

Liu, Q., Jin, X., Cheng, J., Zhou, H., Zhang, Y., & Dai, Y. (2023). Advances in the application of molecular diagnostic techniques for the detection of infectious disease pathogens (Review). *Molecular Medicine Reports*, *27*(5), 104.https://doi.org/10.3892/mmr.2023.12991

Maleki Varnosfaderani, S., & Forouzanfar, M. (2024). The Role of AI in Hospitals and Clinics: Transforming Healthcare in the 21st Century. Bioengineering, 11(4), 337. <https://doi.org/10.3390/bioengineering11040337>

Neale, G., Hogan, H., & Sevdalis, N. (2011). Misdiagnosis: Analysis based on case record review with proposals aimed to improve diagnostic processes. Clinical Medicine, 11(4), 317. <https://doi.org/10.7861/clinmedicine.11-4-317>

Lazcka, O., Campo, F. J. D., & Muñoz, F. X. (2007). Pathogen detection: A perspective of traditional methods and biosensors. Biosensors and Bioelectronics, 22(7), 1205-1217. <https://doi.org/10.1016/j.bios.2006.06.036>

Peaper, D. R., Kerantzas, C. A., & Durant, T. J. (2022). Advances in molecular infectious diseases testing in the time of COVID-19. Clinical Biochemistry, 117, 94. <https://doi.org/10.1016/j.clinbiochem.2022.02.005>

Peeling, R. W., Heymann, D. L., Teo, Y., & Garcia, P. J. (2021). Diagnostics for COVID-19: Moving from pandemic response to control. Lancet (London, England), 399(10326), 757. <https://doi.org/10.1016/S0140-6736(21)02346-1>

Priyanka, B., Patil, R. K., & Dwarakanath, S. (2016). A review on detection methods used for foodborne pathogens. The Indian Journal of Medical Research, 144(3), 327. <https://doi.org/10.4103/0971-5916.198677>

Schiff, G. D. (2009). Diagnostic Error in Medicine. *Archives of Internal Medicine*, *169*(20), 1881. <https://doi.org/10.1001/archinternmed.2009.333>

Solga, S. F., Spacek, L. A., & Risby, T. H. (2020). Challenges in clinical breath research development. Breathborne Biomarkers and the Human Volatilome (Second Edition), 601-613. <https://doi.org/10.1016/B978-0-12-819967-1.00036-0>

Syed, S., Rahaman, A., Mondal, A., Shaligram, S., & Pawar, S. P. (2024). Diagnosis of infectious diseases: complexity to convenience. *Sensors & Diagnostics*, *3*(3), 354–380. <https://doi.org/10.1039/D3SD00236E>

Thomas, Q. D., Colard-Thomas, J., Delansay, D., Leenhardt, F., Solassol, J., Vendrell, J. A., & Quantin, X. (2022). Case report: Liquid biopsy, the sooner the better? Frontiers in Oncology, 12, 1089108. <https://doi.org/10.3389/fonc.2022.1089108>

Ulivi, P., Passardi, A., Marisi, G., Chiadini, E., Molinari, C., Canale, M., Pasini, L., Ferroni, F., Frassineti, G. L., Bartolini, G., & Monti, M. (2021). Case Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences. Frontiers in Pharmacology, 12, 745701. <https://doi.org/10.3389/fphar.2021.745701>

World Health Organization. (n.d.). Rapid diagnostic tests for malaria. World Health Organization. <https://www.who.int/teams/global-malaria-programme/case-management/diagnosis/rapid-diagnostic-tests>

Wambani, J., & Okoth, P. (2022). Impact of Malaria Diagnostic Technologies on the Disease Burden in the Sub-Saharan Africa. Journal of Tropical Medicine, 2022, 7324281. <https://doi.org/10.1155/2022/7324281>

Zimmern, R. L. (2009). Testing challenges: Evaluation of novel diagnostics and molecular biomarkers. Clinical Medicine, 9(1), 68. <https://doi.org/10.7861/clinmedicine.9-1-68>

Zhang, H., Fink, G., & Cohen, J. (2024a). Malaria Rapid Tests, Febrile Illness Management, and Child Mortality Across Sub-Saharan African Countries. *JAMA*, *332*(15), 1270. <https://doi.org/10.1001/jama.2024.12589>